Novartis | Pharmatell

Eyes on Pharma

Check-out What Intel Caught our Eye

Dec 1116 min read

Eyes on 3Q24 Financial Results

We've highlighted a few firms: Lilly, AbbVie, Pfizer, Novo Nordisk, BMS, Roche, Novartis, Merck, AstraZeneca, GSK, Viatris, Teva, and Amgen.

Jan 223 min read

Eyes on the New Year - 2024 has a Busy Start with Deals and Approvals

2024 is off to a busy start with M&A activities highlighted at the JP Morgan Healthcare Conference, plus another Genetic Medicines approval.